HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · Real-Time Price · USD
17.96
+1.21 (7.22%)
Nov 20, 2024, 4:00 PM EST - Market closed
HUTCHMED (China) Employees
HUTCHMED (China) had 1,988 employees as of December 31, 2023. The number of employees decreased by 37 or -1.83% compared to the previous year.
Employees
1,988
Change (1Y)
-37
Growth (1Y)
-1.83%
Revenue / Employee
$307,246
Profits / Employee
-$21,112
Market Cap
3.07B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Amedisys | 19,000 |
Surgery Partners | 13,500 |
Warby Parker | 3,473 |
LivaNova | 2,900 |
TransMedics Group | 584 |
Amicus Therapeutics | 517 |
SpringWorks Therapeutics | 305 |
Xenon Pharmaceuticals | 259 |
HCM News
- 1 day ago - HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee - GlobeNewsWire
- 15 days ago - HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress - GlobeNewsWire
- 21 days ago - HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda - GlobeNewsWire
- 5 weeks ago - HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial - GlobeNewsWire
- 7 weeks ago - HUTCHMED (China) Ltd (HCM) Shares Up 2.9% on Oct 2 - GuruFocus
- 2 months ago - HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda - GlobeNewsWire
- 2 months ago - HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer - GlobeNewsWire
- 2 months ago - HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China - GlobeNewsWire